Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
Single centre, open-label, randomised, three-way crossover study in 18 healthy subjects (9 males and 9 females). The study consisted of three consecutive single-dose treatment periods separated by a washout period of 7 days or more. On each treatment period, the volunteers received a single dose of BIA 2-093 800 mg, orally.
Epistemonikos ID: aa02457136319dfd8427849d98b7d4948bab74fc
First added on: May 12, 2024